Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC

NCT03884192 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

162

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG: Consolidation Sintilimab

Sponsor

Shandong Cancer Hospital and Institute